Teva’s glatiramer fails endpoint in Phase II ALS trial

Results show that GA 40mg was safe and well-tolerated in ALS patients, however, the study’s primary and secondary endpoints were not met. The study was designed to assess the safety, tolerability and efficacy of glatiramer acetate (GA) 40mg, given once daily as a subcutaneous injection, in reducing disease-related functional deterioration in amyotrophic lateral sclerosis (AML) patients.

Vincent Meininger, principal investigator of the study, said: “Despite our hopes and desires, similar to other drug candidates for the treatment of ALS, GA 40 mg did not prove beneficial for ALS patients but was shown to be safe and well tolerated.”